{"nctId":"NCT02493452","briefTitle":"Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)","startDateStruct":{"date":"2015-06"},"conditions":["Irritable Bowel Syndrome Characterized by Constipation"],"count":1135,"armGroups":[{"label":"3.0 mg plecanatide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Plecanatide"]},{"label":"6.0 mg plecanatide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Plecanatide"]},{"label":"Matching placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Plecanatide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n• Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C\n\nExclusion Criteria:\n\n* Refusal or inability to sign informed consent for the trial\n* Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires\n* BMI ≥ 40 or \\< 18\n* Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial\n* Women who are pregnant or lactating\n* Diagnosis of IBS-D or IBS-M\n* Organic or obstructive disease of the small or large intestine\n* Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)\n* Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication\n* Unstable medical illness\n* Bilirubin \\> 3X ULN in the absence of a conjugation defect\n* Any laboratory value \\> 3X ULN unless discussed and approved by the study Medical Monitor","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Overall Responders - ITT Population","description":"An Overall Responder was a patient who was a weekly responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least 1 complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"91","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks","description":"An Abdominal Pain Intensity Responder was a patient who had a decrease of 30 % from baseline for abdominal pain intensity. Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"129","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks","description":"A Stool Frequency Responder was a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"148","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Sustained Efficacy Responders","description":"A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Stool Consistency","description":"Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS). Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7:\n\n1. Separate hard lumps, like nuts (hard to pass)\n2. Sausage-shaped but lumpy\n3. Like a sausage but with cracks on its surface\n4. Like a sausage or snake, smooth and soft\n5. Soft blobs with clear-cut edges (passed easily)\n6. Fluffy pieces with ragged edges, a mushy stool\n7. Watery, no solid pieces, entirely liquid","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"1.029"},{"groupId":"OG001","value":"1.91","spread":"0.902"},{"groupId":"OG002","value":"1.86","spread":"0.912"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"1.579"},{"groupId":"OG001","value":"1.55","spread":"1.631"},{"groupId":"OG002","value":"1.45","spread":"1.621"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Straining","description":"Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.75","spread":"1.848"},{"groupId":"OG001","value":"6.84","spread":"1.860"},{"groupId":"OG002","value":"6.87","spread":"1.920"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.66","spread":"2.149"},{"groupId":"OG001","value":"-2.35","spread":"2.540"},{"groupId":"OG002","value":"-2.35","spread":"2.556"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CSBMs (CSBMs/Week)Complete Spontaneous Bowel Movement","description":"Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.465"},{"groupId":"OG001","value":"0.26","spread":"0.530"},{"groupId":"OG002","value":"0.27","spread":"0.527"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"1.779"},{"groupId":"OG001","value":"1.23","spread":"2.303"},{"groupId":"OG002","value":"1.63","spread":"3.042"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a SBM Within 24 Hours After First Dose of Study Medication","description":"A responder was any patient with a SBM within 24 hours after the first dose of study drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"157","spread":null},{"groupId":"OG002","value":"167","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Abdominal Pain","description":"Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (None) to 10 (Worst Possible). Baseline was the mean of the non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The average daily abdominal pain score was the average of the non-missing worst daily abdominal pain scores (on a 0 to 10 scale) in the given week.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.40","spread":"1.624"},{"groupId":"OG001","value":"6.56","spread":"1.634"},{"groupId":"OG002","value":"6.48","spread":"1.714"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.42","spread":"2.116"},{"groupId":"OG001","value":"-2.00","spread":"2.226"},{"groupId":"OG002","value":"-1.87","spread":"2.297"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":376},"commonTop":["Diarrhea","Headache"]}}}